{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:19:28Z","timestamp":1790662768785,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.vaccine.2018.11.028","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T19:13:22Z","timestamp":1543000402000},"page":"80-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Increasing FIM2\/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro"],"prefix":"10.1016","volume":"37","author":[{"given":"Anne Marie","family":"Queenan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Ki","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellen","family":"Fa\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer E.","family":"Brightman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Serroyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Wiertsema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Fortanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germie","family":"van den Dobbelsteen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Poolman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.11.028_b0005","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/infdis\/jit491","article-title":"Pertussis resurgence: perspectives from the Working Group Meeting on pertussis on the causes, possible paths forward, and gaps in our knowledge","volume":"209","author":"Burns","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.028_b0010","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1586\/14760584.2014.944167","article-title":"Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology","volume":"13","author":"Sheridan","year":"2014","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.11.028_b0015","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00034-17","article-title":"Waning immunity and microbial vaccines-workshop of the national institute of allergy and infectious diseases","volume":"24","author":"Gu","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.11.028_b0020","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1586\/14760584.2014.932254","article-title":"Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines","volume":"13","author":"Hegerle","year":"2014","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.11.028_b0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1574-695X.2005.00001.x","article-title":"Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies","volume":"46","author":"Rodriguez","year":"2006","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2018.11.028_b0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0882-4010(92)90115-5","article-title":"Construction and analysis of Bordetella pertussis mutants defective in the production of fimbriae","volume":"12","author":"Mooi","year":"1992","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2018.11.028_b0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0264-410X(89)90193-X","article-title":"Serospecific protection of mice against intranasal infection with Bordetella pertussis","volume":"7","author":"Robinson","year":"1989","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.028_b0040","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/S0264-410X(02)00158-5","article-title":"Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection","volume":"20","author":"Denoel","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.028_b0045","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)06508-2","article-title":"Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines","volume":"350","author":"Olin","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.11.028_b0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJM199602083340602","article-title":"A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine","volume":"334","author":"Gustafsson","year":"1996","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2018.11.028_b0055","unstructured":"WHO Weekly epidemiological record No. 35, 2015;90:433\u2013460."},{"key":"10.1016\/j.vaccine.2018.11.028_b0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1586\/14760584.6.1.47","article-title":"Acellular pertussis vaccines and the role of pertactin and fimbriae","volume":"6","author":"Poolman","year":"2007","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.11.028_b0065","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1586\/14760584.2014.930667","article-title":"Bordetella pertussis fimbriae (Fim): relevance for vaccines","volume":"13","author":"Gorringe","year":"2014","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.11.028_b0070","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00500-15","article-title":"Cooperative roles for fimbria and filamentous hemagglutinin in Bordetella adherence and immune modulation","volume":"6","author":"Scheller","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2018.11.028_b0075","unstructured":"Guide for the Care and use of Laboratory Animals. 8th ed. Washington, DC, USA, The National Academies Press; 2011."},{"issue":"6","key":"10.1016\/j.vaccine.2018.11.028_b0080","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1016\/j.vaccine.2018.11.028_b0085","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMc1209369","article-title":"Pertactin-negative variants of Bordetella pertussis in the United States","volume":"368","author":"Queenan","year":"2013","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2018.11.028_b0090","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1016\/j.vaccine.2005.06.021","article-title":"Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model","volume":"23","author":"Denoel","year":"2005","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2018.11.028_b0095","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1586\/14760584.2014.938642","article-title":"The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines","volume":"13","author":"Queenan","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.11.028_b0100","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1128\/CVI.00061-10","article-title":"Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens","volume":"18","author":"Stenger","year":"2011","journal-title":"Clin Vaccine Immunol : CVI"},{"key":"10.1016\/j.vaccine.2018.11.028_b0105","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1128\/iai.48.2.422-427.1985","article-title":"Purification and characterization of fimbriae isolated from Bordetella pertussis","volume":"48","author":"Zhang","year":"1985","journal-title":"Infect Immunol"},{"key":"10.1016\/j.vaccine.2018.11.028_b0110","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M115.055541","article-title":"Adjuvant-induced human monocyte secretome profiles reveal adjuvant- and age-specific protein signatures","author":"Oh","year":"2016","journal-title":"Mol Cell Proteom: MCP"},{"key":"10.1016\/j.vaccine.2018.11.028_b0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cyto.2016.04.001","article-title":"In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant","volume":"83","author":"van Haren","year":"2016","journal-title":"Cytokine"},{"issue":"32","key":"10.1016\/j.vaccine.2018.11.028_b0120","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1016\/j.vaccine.2012.05.002","article-title":"Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo","volume":"30","author":"Zaitseva","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.028_b0125","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3389\/fimmu.2016.00562","article-title":"A Meningococcal outer membrane vesicle vaccine incorporating genetically attenuated endotoxin dissociates inflammation from immunogenicity","volume":"7","author":"Dowling","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.11.028_b0130","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijmm.2004.07.007","article-title":"Diphtheria-tetanus-pertussis (DTP) combination vaccines and evaluation of pertussis immune responses","volume":"294","author":"Godfroid","year":"2004","journal-title":"Int J Med Microbiol: IJMM"},{"key":"10.1016\/j.vaccine.2018.11.028_b0135","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/S0264-410X(99)00037-7","article-title":"Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines","volume":"17","author":"Guiso","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.028_b0140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/cid\/ciu788","article-title":"Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage","volume":"60","author":"Martin","year":"2015","journal-title":"Clin Infect Dis : Off Publ Infect Dis Soc Am"},{"issue":"46","key":"10.1016\/j.vaccine.2018.11.028_b0145","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1016\/j.vaccine.2015.09.064","article-title":"Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model","volume":"33","author":"Safarchi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.028_b0150","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1600-0463.2009.02521.x","article-title":"Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2\/3 antibodies after vaccination and infection","volume":"117","author":"Hallander","year":"2009","journal-title":"APMIS : Acta pathologica, microbiologica, et immunologica Scandinavica"},{"issue":"20","key":"10.1016\/j.vaccine.2018.11.028_b0155","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0264-410X(98)00227-8","article-title":"Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis","volume":"16","author":"Storsaeter","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.028_b0160","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1542\/peds.96.3.548","article-title":"Comparison of 13 acellular pertussis vaccines: overview and serologic response","volume":"96","author":"Edwards","year":"1995","journal-title":"Pediatrics"},{"issue":"3 Pt 2","key":"10.1016\/j.vaccine.2018.11.028_b0165","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1542\/peds.96.3.547","article-title":"Multicenter acellular pertussis vaccine trial: a National Institutes of Health perspective","volume":"96","author":"Klein","year":"1995","journal-title":"Pediatrics"},{"issue":"3 Pt 2","key":"10.1016\/j.vaccine.2018.11.028_b0170","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1542\/peds.96.3.557","article-title":"Comparison of 13 acellular pertussis vaccines: adverse reactions","volume":"96","author":"Decker","year":"1995","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.028_b0175","doi-asserted-by":"crossref","first-page":"e1003264","DOI":"10.1371\/journal.ppat.1003264","article-title":"Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine","volume":"9","author":"Ross","year":"2013","journal-title":"PLoS Pathog"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.028_b0180","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/mi.2012.117","article-title":"Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates","volume":"6","author":"Warfel","year":"2013","journal-title":"Mucosal Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.028_b0185","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/CVI.00438-14","article-title":"Immune responses to pertussis antigens in infants and toddlers after immunization with multicomponent acellular pertussis vaccine","volume":"21","author":"Fadugba","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.028_b0190","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1128\/IAI.06310-11","article-title":"Nonhuman primate model of pertussis","volume":"80","author":"Warfel","year":"2012","journal-title":"Infect Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18315512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18315512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:29:22Z","timestamp":1759400962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18315512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0264410X18315512"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increasing FIM2\/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}